Canadian officials warn about counterfeit Ozempic and Mounjaro products.

Health Canada says counterfeit versions of GLP-1 drugs such as Ozempic and Mounjaro are being sold in stores and online, and the agency has not assessed these unauthorized products for safety, effectiveness or quality.

Health Canada has issued a public advisory warning that counterfeit versions of GLP-1 drugs, including Ozempic and Mounjaro, are appearing in stores and online across Canada. The agency said some websites and social media advertisements misuse official Health Canada logos and display fake endorsements to mislead consumers. The advisory comes as GLP-1 therapies have drawn increased public attention for diabetes care and weight management. Key details: - Health Canada reported unauthorized versions of semaglutide-based and other GLP-1 products are being sold both in physical retailers and online. - The agency said these products have not been assessed for safety, effectiveness or quality and may contain incorrect, unlisted, or contaminated ingredients. - Health Canada noted misuse of its logos in advertising and warned retailers that selling unauthorized products or making false treatment claims is illegal in Canada. - The advisory said consumers can look for an eight-digit Drug Identification Number (DIN) on labels as an identifier of authorized products. Summary: The advisory highlights potential health risks tied to unauthorized GLP-1 products and aims to inform consumers and retailers about those risks. Health Canada reported concerns including inaccurate active ingredient levels, unlisted substances, and possible contamination or sterility issues with injectable products. Undetermined at this time.